YOLFTbeta
22

Genolution Inc.

225220 · KQ · Healthcare / Biotechnology

1,734.00KRW+1.00 (+0.06%)

Price History

Full chart

Market Stats

Previous Close1,733.00
Open1,715.00
Day Range1,710.00 – 1,748.00
52-Week Range957.00 – 2,330.00
Volume25.79K
Market Cap26.83B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.13
50-Day Avg1,381.12
200-Day Avg1,646.60

About

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits. It also develops and manufactures instruments and reagents for DNA/RNA; provides long dsRNA synthesis services; and siRNA/miRNA/shRNA synthesis service and related products. Genolution Inc. was founded in 2006 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ki-Ok Kim
  • Employees75
  • Headquarters63 Magokjungang 8-ro 3-gil, Seoul, South Korea, 05836, Korea
  • Websitehttps://genolution.co.kr

Leadership

  • Mr. Ki-Ok KimCo-CEO & Representative Director · b. 1955
  • Ms. MinYi Kim Ph.D.Co-CEO & Representative Director · b. 1986
  • Mr. Sanghun KimChief Financial Officer · b. 1960
  • Mr. WooJin KimManaging Director · b. 1969
  • Mr. SunShin LeeManaging Director · b. 1961
  • Mr. JungHoon ParkManaging Director · b. 1974

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.50B2.44B3.13B3.95B85.30B72.83B38.08B9.76B7.14B9.40B
Growth (%)-+62.60%+28.38%+26.17%+2059.22%-14.62%-47.71%-74.37%-26.90%+31.79%
Cost of Revenue268.85M547.76M837.73M1.35B22.05B19.44B11.73B5.24B4.77B5.88B
Gross Profit1.23B1.89B2.29B2.60B63.25B53.40B26.35B4.52B2.37B3.53B
Gross Margin82.08%77.54%73.25%65.71%74.15%73.31%69.20%46.32%33.18%37.49%
Operating Expense1.15B1.26B2.11B2.45B9.21B12.11B11.35B12.66B11.86B12.17B
Operating Income77.96M628.23M182.63M148.02M54.04B41.28B15.00B-8.14B-9.49B-8.64B
Operating Margin5.20%25.76%5.83%3.75%63.35%56.68%39.38%-83.35%-132.96%-91.89%
EBITDA------18.88B-5.51B-4.31B-9.35B
EBITDA Margin------49.57%-56.48%-60.44%-99.39%
Net Income88.06M577.05M1.29B-286.99M32.05B34.39B14.60B-5.55B-6.83B-11.64B
Net Income Margin5.87%23.66%41.26%-7.26%37.57%47.22%38.34%-56.86%-95.65%-123.80%
R&D----462.70M1.65B1.52B3.08B1.67B471.61M
R&D as % of Total Revenue----0.54%2.26%3.98%31.57%23.43%5.01%
Interest Expense0001.84M1.70M188.09M311.60M-418.09M875.62M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.05%0.00%0.26%0.82%-5.86%9.31%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.99B4.71B11.10B13.43B83.77B94.94B114.45B113.44B106.45B93.79B
Total Liabilities570.62M704.01M8.16B10.79B22.48B12.74B19.75B25.99B26.16B25.91B
Total Equity3.42B4.00B2.94B2.64B61.29B82.20B94.70B87.45B80.29B68.40B
Cash2.18B1.95B812.00K3.62B43.96B2.98M12.45M2.63M1.07M18.80B
Total Debt--1.64B3.55B6.65B-----
Net Debt------9.49B17.92B-5.06B

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-27.00M717.13M147.49M-80.58M45.97B25.73B13.55B-1.14B-1.43B-7.01B
Investing Cash Flow-395.11M-941.30M-2.93B-3.18B-18.30B-23.07B-51.46B-7.08B25.69B-
Financing Cash Flow1.50B05.83B1.85B15.35B-15.09B9.15B7.16B373.20M-
Capital Expenditure356.27M861.62M2.92B3.14B8.68B5.13B22.54B6.88B12.19B442.67M
Free Cash Flow----4.72B36.42B20.60B-8.99B-8.02B-13.62B-7.45B
Dividends Paid-----5.23B1.81B0--
FCF to OCF---5854.95%79.22%80.06%-66.37%706.16%950.57%106.31%
Dividend Paid to FCF-----25.41%-20.13%0.00%--

Earnings

Report DateSep 30, 2020Dec 31, 2020May 11, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022May 15, 2023Aug 14, 2023Nov 14, 2023Mar 22, 2024May 17, 2024Aug 14, 2024Nov 12, 2024Mar 19, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 18, 2026May 13, 2026Jun 30, 2026
EPS Estimate------------------------
EPS Actual698.81772.191200.71409.42415.84363.78646.83132.04171.25-196.0632.94-85.13-21.19-229.712.00-122.65-172.56-84.82-115.04-195.61-50.84-283.1233.0542.89
Surprise------------------------
Timing----------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap26.83B
Enterprise Value23.19B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.67
Price / Book0.37
Revenue (TTM)10.03B
Gross Profit (TTM)3.10B
EBITDA-5.78B
Profit Margin-46.46%
Operating Margin-51.57%
Return on Equity-7.88%
Return on Assets-4.76%
Shares Outstanding18.08M
Shares Float16.35M
Beta0.13
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20222×
200.00Dec 28, 2022200.00Sep 29, 2022
20212×
99.01Dec 29, 202199.01Sep 29, 2021
20201×
173.27Dec 29, 2020

Stock Splits

  • Apr 19, 20232:1
  • Dec 28, 2022101:100
  • Apr 8, 20212:1